Brian Derubertis News Today

In patients with severe artery blockage in the lower leg, an artery-supporting device called a resorbable scaffold is superior to angioplasty, according to the results of a large international clinical trial co-led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.

Abbott's landmark LIFE-BTK randomized clinical trial met its primary safety and effectiveness endpoints, demonstrating that Esprit BTK offers significant advancements in opening and keeping blocked arteries below-the-knee open compared to the standard of care, balloon angioplasty 

Abbott (NYSE:ABT) today announced data supporting its Esprit BTK everolimus-eluting resorbable scaffold system.

Abbotts new investigational drug-eluting Esprit BTK (below-the-knee) resorbable scaffold is made of naturally dissolving material that disappears over time...

Abbotts new investigational drug-eluting Esprit BTK resorbable scaffold is made of naturally dissolving material that disappears over time after its opened a clogged arteryThere is a significant...

17th Annual Leipzig Interventional Course (LINC) will ‘Connect the World’ with a Virtual Format Share Article Premier interdisciplinary course on endovascular interventions will deliver expanded education, including a record number of live cases “No matter the circumstances, LINC remains committed to providing a platform for the interdisciplinary exchange of the latest scientific data and technical aspects of endovascular interventions for specialists,” said Dierk Scheinert, MD, founder...